Achieving lipid targets in primary care settings

Current Medical Research and Opinion

Volumn 30, Issue 10, 2014, Pages 1971-1974

  Katsiki, Niki ^a   Athyros, Vasilios G ^a   Karagiannis, Asterios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

High density lipoprotein cholesterol; Low density lipoprotein cholesterol; Multifactorial treatment; Small dense low density lipoprotein cholesterol; Statins; Triglycerides

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KEXIN; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; SERINE PROTEINASE; SIMVASTATIN; TRIACYLGLYCEROL;

CARDIOVASCULAR RISK; CLINICAL PRACTICE; GLYCEMIC CONTROL; HUMAN; NONALCOHOLIC FATTY LIVER; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; REVIEW; RISK REDUCTION; BLOOD; CARDIOVASCULAR DISEASES; PRIMARY HEALTH CARE; PROCEDURES; RISK FACTOR;

CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; PRIMARY HEALTH CARE; RISK FACTORS; TRIGLYCERIDES;

EID: 84925238699     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.941978     Document Type: Review

References (32)

1. Jameson K, Zhang Q, Zhao C, et al. Total and low-density lipoprotein cholesterol in high-risk patients treated with atorvastatin monotherapy in the United Kingdom: analysis of a primary-care database. Curr Med Res Opin 2014;30:655-65
2. Koenigsfeld CF, Horning KK, Logemann CD, et al. Medication therapy management in the primary care setting: a pharmacist-based pay-for-performance project. J Pharm Pract 2012;25:89-95
3. Gitt AK, Juenger C, Smolka W, et al. Impact of a budget-restrictive (Germany) versus an incentive-driven (UK) reimbursement system on LDL goal achievement in statin-treated patients for secondary prevention: results of DYSIS. European Society of Cardiology 2013 Congress, 2 September 2013, Amsterdam, the Netherlands. Eur Heart J 2013;34(Abstract Suppl):3689
4. European Society of Cardiology Press Office. EUROASPIRE IV reveals success and challenges in secondary prevention of CVD across Europe. 2013. Available at: http://www.escardio.org/about/press/press-releases/esc13-amsterdam/Pages/euroaspire-iv-success-challenges-secondary-prevention-CVD-europe.aspx [Last accessed 30 June 2014]
5. Athyros VG, Hatzitolios A, Karagiannis A, et al.; IMPERATIVE Collaborative Group. IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci 2011;7:984-92
6. Athyros VG, Tziomalos K, Gossios TD, et al.; GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376:1916-22
7. Tikkanen MJ, Fayyad R, Faergeman O, et al.; IDEAL Investigators. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 2013;168:3846-52
8. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007;22:118-27
9. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004;57:728-34
10. Shepherd J, Kastelein JJ, Bittner V, et al.; Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2007;2:1131-9
11. Colhoun HM, Betteridge DJ, Durrington PN, et al.; CARDS Investigators. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009;54:810-19
12. Shepherd J, Kastelein JJ, Bittner V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008;51:1448-54
13. Baigent C, Landray MJ, Reith C, et al.; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-92
14. Milionis HJ, Rizos E, Mikhailidis DP. Smoking diminishes the beneficial effect of statins: observations from the landmark trials. Angiology 2001;52:575-87
15. Cheung BM, Lauder IJ, Lau CP, et al. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 2004;57:640-51
16. Athyros VG, Tziomalos K, Katsiki N, et al.; GREACE Study Collaborative Group. The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study. Curr Vasc Pharmacol 2013;11:779-84
17. Frey P, Waters DD, DeMicco DA, et al. Impact of smoking on cardiovascular events in patients with coronary disease receiving contemporary medical therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] trials). Am J Cardiol 2011;107:145-50
18. Warren JR, Falster MO, Fox D, et al. Factors influencing adherence in long-term use of statins. Pharmacoepidemiol Drug Saf 2013;22:1298-307
19. Carey IM, DeWilde S, Shah SM, et al. Statin use after first myocardial infarction in UK men and women from 1997 to 2006: who started and who continued treatment? Nutr Metab Cardiovasc Dis 2012;22:400-8
20. Azar ST, Hantash HA, Jambart S, et al. Factors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International Study. Vasc Health Risk Manag 2014;10:225-35
21. Merck Making News. Results from HPS2-THRIVE Study of TREDAPTIVE™ (extended-release niacin/laropiprant) Presented at American College of Cardiology Scientific Sessions. 2013. Available at: http://www.mercknewsroom.com/press-release/research-and-development-news/results-hps2-thrive-study-tredaptive-extended-release-ni [Last accessed 30 June 2014]
22. Mikhailidis DP, Athyros VG. Dyslipidaemia in 2013: new statin guidelines and promising novel therapeutics. Nat Rev Cardiol 2014;11:72-4
23. Athyros VG, Karagiannis A, Ganotakis ES, et al.; Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT) Collaborative Group. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin 2011;27:1659-68
24. Vaccaro O, Franzini L, Miccoli R, et al.; MIND.IT Study Group. Feasibility and effectiveness in clinical practice of a multifactorial intervention for the reduction of cardiovascular risk in patients with type 2 diabetes: the 2-year interim analysis of the MIND.IT study: a cluster randomized trial. Diabetes Care 2013;36:2566-72
25. Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 2011;9:258-70
26. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, et al. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 2012;51:314-24
27. Mikhailidis DP, Elisaf M, Rizzo M, et al. European panel on low density lipoprotein (LDL) subclasses: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011;9:533-71
28. Katsiki N, Theocharidou E, Karagiannis A, et al. Ezetimibe therapy for dyslipidemia: an update. Curr Pharm Des 2013;19:3107-14
29. Katsiki N, Nikolic D, Montalto G, et al. The role of fibrate treatment in dyslipidemia: an overview. Curr Pharm Des 2013;19:3124-31
30. Singh A, Schwartzbard A, Gianos E, et al. What should we do about hypertriglyceridemia in coronary artery disease patients? Curr Treat Options Cardiovasc Med 2013;15:104-17
31. Mikhailidis DP, Lawson RW, McCormick AL, et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Curr Med Res Opin 2011;27:1191-210
32. Jones MR, Nwose OM. Role of colesevelam in combination lipid-lowering therapy. Am J Cardiovasc Drugs 2013;13:315-23